Markers of inflammation in patients with heart failure in association with chronic kidney disease

Abstract

Aim. Evaluation of markers of systemic inflammation in patients with chronic heart failure in comorbidity with chronic kidney disease.

Methods. The study included 188 patients with heart failure and kidney disease including control group (76 patients) with heart failure with preserved renal function aged 38 to 83 years (mean age 66.8±10.1 years), with the duration of heart failure of about 8 years. Quantitative measurement of C-reactive protein and proteins of blood serum and daily excretion of protein with urine were performed.

Results. Glomerular filtration rate in patients without renal pathology was 71.1±11.7 ml/min/1.73 m2, and in the group with heart failure associated with kidney dysfunction it was 51.5±19.1 ml/min/1.73 m2. C-reactive protein, γ-globulin, albumin and total serum protein in patients with chronic kidney disease differed from those in patients with heart failure without kidney damage.

Conclusion. C-reactive protein and γ-globulin in the serum significantly increase in patients with heart failure and chronic kidney disease and can be used as markers of cardiac as well as renal events.

Keywords

chronic heart failure / chronic kidney disease / inflammatory biomarkers

References

[1] Белоглазов В.А., Климчук А.В. Антиэндотоксиновый иммунитет и уровень С-реактивного белка у больных хронической болезнью почек, находящихся на диализе. Таврический мед.-биол. вестн. 2013; 4 (64): 25-28.

[2] Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность. Клин. мед. 2012; 90 (10): 4-11.

[3] Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвёртый пересмотр). Сердечная недостаточность. 2013; 14 (7): 379-472.

[4] Милютина О.В., Чичерина Е.Н. Прогностическая роль С-реактивного белка в развитии риска кардиальных событий. Рос. кардиол. ж. 2011; 1 (87): 71-73.

[5] Насыбуллина А.А., Булашова О.В., Хазова Е.В. и др. Кардиоренальные взаимоотношения: эволюция взглядов. Практич. мед. 2015; 3-2 (88): 46-49.

[6] Серов В.А., Шутов А.М., Мензоров М.В. и др. Эпидемиология хронической болезни почек у больных с хронической сердечной недостаточностью. Нефрология. 2010; 14 (1): 50-55.

[7] Adams K.F., Fonarow G.C., Emerman C.L et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 2005; 149 (2): 209-216. http://dx.doi.org/10.1016/j.ahj.2004.08.005

[8] Ahmed A., Rich M.W., Sanders P.W. et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am. J. Cardiol. 2007; 99: 393-398. http://dx.doi.org/10.1016/j.amjcard.2006.08.042

[9] Damman K., Testani J.M. The kidney in heart failure: an update. Eur. Heart J. 2015; 36 (23): 1437-1444. http://dx.doi.org/10.1093/eurheartj/ehv010

[10] Levey A.S., Eckardt K.U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100. http://dx.doi.org/10.1111/j.1523-1755.2005.00365.x

[11] Matsushita K., van der Velde M., Astor B.C et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375 (9731): 2073-2081. http://dx.doi.org/10.1016/S0140-6736(10)60674-5

[12] Ronco C., McCullough P., Anker S.D. et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur. Heart J. 2010; 31: 703-711. http://dx.doi.org/10.1093/eurheartj/ehp507

[13] Tokmakova M.P., Skali H., Kenchaiah S. et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the survival and ventricular enlargement (SAVE) study. Circulation. 2004; 110: 3667-3673. http://dx.doi.org/10.1161/01.CIR.0000149806.01354.BF

[14] Van Deursen V.M., Urso R., Laroche C. et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur. J. Heart Fail. 2014; 16 (1): 103-111. http://dx.doi.org/10.1002/ejhf.30

[15] Vasan R.S., Sullivan L.M., Roubenoff R. et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003; 107: 1486-1491. http://dx.doi.org/10.1161/01.CIR.0000057810.48709.F6

RIGHTS & PERMISSIONS

Nasybullina A.A., Bulashova O.V., Gazizyanova V.M., Malkova M.I., Mustafin E.E., Khusnutdinova G.R.